HCM vs. INSM, AXSM, CRNX, PBH, RARE, PRGO, ALKS, BHVN, SMMT, and IDYA
Should you be buying HUTCHMED stock or one of its competitors? The main competitors of HUTCHMED include Insmed (INSM), Axsome Therapeutics (AXSM), Crinetics Pharmaceuticals (CRNX), Prestige Consumer Healthcare (PBH), Ultragenyx Pharmaceutical (RARE), Perrigo (PRGO), Alkermes (ALKS), Biohaven (BHVN), Summit Therapeutics (SMMT), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical preparations" industry.
HUTCHMED (NASDAQ:HCM) and Insmed (NASDAQ:INSM) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability, community ranking and valuation.
HUTCHMED has higher revenue and earnings than Insmed.
HUTCHMED currently has a consensus price target of $29.70, indicating a potential upside of 47.83%. Insmed has a consensus price target of $44.71, indicating a potential upside of 75.08%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than HUTCHMED.
In the previous week, Insmed had 24 more articles in the media than HUTCHMED. MarketBeat recorded 30 mentions for Insmed and 6 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.58 beat Insmed's score of 0.39 indicating that HUTCHMED is being referred to more favorably in the media.
HUTCHMED has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Insmed has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.
8.8% of HUTCHMED shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by insiders. Comparatively, 4.6% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Insmed received 193 more outperform votes than HUTCHMED when rated by MarketBeat users. However, 66.60% of users gave HUTCHMED an outperform vote while only 64.79% of users gave Insmed an outperform vote.
HUTCHMED has a net margin of 0.00% compared to Insmed's net margin of -236.74%.
Summary
Insmed beats HUTCHMED on 8 of the 15 factors compared between the two stocks.
Get HUTCHMED News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HUTCHMED Competitors List
Related Companies and Tools
